Email this article 
KAJIAN PUSTAKA : HASIL KLINIS DAN EFEK SAMPING PENGGUNAAN BEDAKUILIN TERHADAP PASIEN TB MDR DAN XDR
Abstract
Resistance to isoniazid and rifampin antibiotics, which are the first-line drugs for the treatment of tuberculosis, is a major concern for public health. The emergence of Multidrug-resistant tuberculosis (MDR TB) bacteria makes TB treatment more difficult and takes longer to cure. After several decades, the newest antituberculosis drug, Bedaquiline, has become an alternative to overcome isoniazid and rifampin resistance. The use of Bedaquiline is currently supervised by health facilities because of its serious side effects. This literature review aims to review the clinical results and side effects of the use of Bedaquiline. The compilation of this literature review was obtained from previous studies regarding clinical outcomes and side effects of using Bedaquiline for MDR and XDR TB patients. Selected articles reported on clinical outcomes and adverse events based on inclusion and exclusion criteria. From 10 articles that met the inclusion criteria, it was found that Bedaquiline can accelerate the conversion of cultures by about 6 months, the side effects vary for each individual and are safe for use in pediatric, adolescent and adult patients.
ABSTRAK
Resistensi antibiotik isoniazid dan rifampisin yang merupakan obat lini pertama pengobatan tuberkulosis menjadi perhatian besar bagi kesehatan masyarakat. Munculnya bakteri Multidrug-resistant tuberkulosis (TB MDR) menyebabkan pengobatan TB akan semakin sulit dan lama untuk disembuhkan. Setelah beberapa dekade obat antituberkulosis terbaru bedakuilin menjadi alternatif untuk mengatasi resistensi isoniazid dan rifampisin. Penggunaan bedakuilin saat ini diawasi oleh fasilitas kesehatan karena efek sampingnya yang cukup serius. Kajian pustaka ini bertujuan untuk mengulas hasil klinis dan efek samping dari penggunaan bedakuilin. Penyusunan kajian pustaka ini didapatkan dari penelitian sebelumnya mengenai hasil klinis dan efek samping penggunaan bedakuilin untuk pasien TB MDR dan XDR. Artikel yang terpilih melaporkan tentang hasil klinis dan efek samping berdasarkan kriteria inklusi dan eksklusi. Dari 10 artikel yang memenuhi kriteria inklusi, didapatkan hasil bahwa bedakuilin dapat mempercepat konversi kultur sekitar 6 bulan, efek samping yang bervariasi pada masing-masing individu dan aman digunakan untuk pasien anak, remaja dan dewasa.
Keywords
References
CDC, Tuberculosis. 2022. https://www.cdc.gov. [Diakses tanggal 20 Februari 2022]
Dhakulkar, S., Das, M., Sutar, N., Oswal, V., Shah, D., Ravi, S., Vengurlekar, D., Chavan, V., Rebello, L., Meneguim, A.C., Iyer, A., Mansoor, H., Kalon, S., Acharya, S., Ferlazzo, G., Isaakidis, P., Thakur, H.P. Treatment outcomes of children and adolescents receiving drug-resistant TB treatment in a routine TB programme, Mumbai, India. PLoS One 16. 2021., 1–12.
Fu, L., Weng, T., Sun, F., Zhang, P., Li, H., Li, Y., Yang, Q., Cai, Y., Zhang, X., Liang, H., Chen, X., Wang, Z., Liu, L., Zhang, W., Deng, G.,. Insignificant difference in culture conversion between bedaquiline-containing and bedaquiline-free all-oral short regimens for multidrug-resistant tuberculosis. International Journal Infection. Disease. 2021. 111, 138–147.
Gao, J.T., Du, J., Wu, G.H., Pei, Y., Gao, M.Q., Martinez, L., Fan, L., Chen, W., Xie, L., Chen, Y., Wang, H., Jin, L., Li, G.B., Zong, P.L., Xiong, Y., Wu, Q.H., Li, M.W., Yan, X.F., Miao, Y.F., Cai, Q.S., Li, X.J., Bai, D.P., Geng, S.J., Yang, G.L., Tang, P.J., Zeng, Y., Chen, X.H., Li, T.X., Cai, C., Zhou, Y., Zhuo, M., Wang, J.Y., Guan, W.L., Xu, L., Shi, J.C., Shu, W., Cheng, L.L., Teng, F., Ning, Y.J., Xie, S.H., Sun, Y.X., Zhang, L.J., Liu, Y.H.,.Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety. Infection. Diseases Poverty 10. 2021. 1–10.
Gordon, S. V., Parish, T. Microbe profile: Mycobacterium tuberculosis: Humanity’s deadly microbial foe. Microbiology. 2018. 437–439.
Khoshnood, S., Goudarzi, M., Taki, E., Darbandi, A., Kouhsari, E., Heidary, M., Motahar, M., Moradi, M., Bazyar, H. Bedaquiline: Current status and future perspectives. Journal Global Antimicroba Resistence. 2021. 48–59.
Koirala, S., Borisov, S., Danila, E., Mariandyshev, A., Shrestha, B., Lukhele, N., Dalcolmo, M., Shakya, S.R., Miliauskas, S., Kuksa, L., Manga, S., Aleksa, A., Denholm, J.T., Khadka, H.B., Skrahina, A., Diktanas, S., Ferrarese, M., Bruchfeld, J., Koleva, A., Piubello, A., Koirala, G.S., Udwadia, Z.F., Palmero, D.J., Munoz-Torrico, M., GC, R., Gualano, G., Grecu, V.I., Motta, I., Papavasileiou, A., Li, Y., Hoefsloot, W., Kunst, H., Mazza-Stalder, J., Payen, M.C., Akkerman, O.W., Bernal, E., Manfrin, V., Matteelli, A., Mustafa Hamdan, H., Nieto Marcos, M., Cadiñanos Loidi, J., Cebrian Gallardo, J.J., Duarte, R., Escobar Salinas, N., Gomez Rosso, R., Laniado-Laborín, R., Martínez Robles, E., Quirós Fernandez, S., Rendon, A., Solovic, I., Tadolini, M., Viggiani, P., Belilovski, E., Boeree, M.J., Cai, Q., Davidavičienė, E., Forsman, L.D., De Los Rios, J., Drakšienė, J., Duga, A., Elamin, S.E., Filippov, A., Garcia, A., Gaudiesiute, I., Gavazova, B., Gayoso, R., Gruslys, V., Jonsson, J., Khimova, E., Madonsela, G., Magis-Escurra, C., Marchese, V., Matei, M., Moschos, C., Nakčerienė, B., Nicod, L., Palmieri, F., Pontarelli, A., Šmite, A., Souleymane, M.B., Vescovo, M., Zablockis, R., Zhurkin, D., Alffenaar, J.W., Caminero, J.A., Codecasa, L.R., García-García, J.M., Esposito, S., Saderi, L., Spanevello, A., Visca, D., Tiberi, S., Pontali, E., Centis, R., D’Ambrosio, L., van den Boom, M., Sotgiu, G., Migliori, G.B. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort. Pulmonology. 2021. 403–412.
Maretbayeva, S.M., Rakisheva, A.S., Adenov, M.M., Yeraliyeva, L.T., Algozhin, Y.Z., Stambekova, A.T., Berikova, E.A., Yedilbayev, A., Rich, M.L., Seung, K.J., Issayeva, A.M.. Culture conversion at six months in patients receiving bedaquiline- and delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis. International Journal Infection Disease. 2021. S91–S95.
Moodliar, R., Aksenova, V., Frias IV, M.V.G., Van de Logt, J., Rossenu, S., Birmingham, E., Zhuo, S., Mao, G., Lounis, N., Kambili, C., Bakare, N. Bedaquiline for multidrug-resistant TB in paediatric patients. International Journal Tuberculosis Lung Disease. 2021. 716–724.
Oelofse, S., Esmail, A., Diacon, A.H., Conradie, F., Olayanju, O., Ngubane, N., Howell, P., Everitt, D., Crook, A.M., Mendel, C.M., Wills, G.H., Olugbosi, M., del Parigi, A., Sun, E., Calatroni, A., Spigelman, M., Dheda, K. Pretomanid with bedaquiline and linezolid for drug-resistant TB: A comparison of prospective cohorts. International Journal Tuberculosis Lung Diseases. 2021. 453–460.
Wang, M.G., Wu, S.Q., He, J.Q. Efficacy of bedaquiline in the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. BMC Infection Diseases. 2021. 1–10.
WHO, Tuberculosis. 2021. https://www.who.int/news-room/fact-sheets/detail/tuberculosis. [Diakses tanggal 20 Februari 2022]
Wu, H.Y., Tian, Y., Wang, X.D., Sun, J.S., Fan, L.C., Chen, M.X., Li, R., Chen, Y. Twenty-four-week interim outcomes of bedaquiline-containing regimens in treatment of adolescents with rifampicin-resistant tuberculosis: A retrospective cohort study in China. Journal Paediatry Child Health. 2022. 116–121.
DOI: http://dx.doi.org/10.52118/edumasda.v6i2.165
Refbacks
- There are currently no refbacks.
Copyright (c) 2022 Tania Rizki Amalia, Andriyani Rahmah Fahriati, Nurihardiyanti Nurihardiyanti, Gina Aulia
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Sekolah Tinggi Ilmu Kesehatan Kharisma Persada
Pajajaran Street Number 1 Pamulang,
South Tangerang City, Banten Province, Indonesia, 15417
Telephone: 021-74716128 / Handphone : 081384462729
Edu Masda Journal by Sekolah Tinggi Ilmu Kesehatan Kharisma Persada is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Based on a work at http://openjournal.masda.ac.id/index.php/edumasda/index.